Mark J. GILBERT
17Patents
4h-index
41Co-inventors
56Inventor score
Filing activity: Mar 4, 2013 → Jun 22, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11413310B2 | Articles of manufacture and methods for treatment using adoptive cell therapy | Human Necessities | 10 | Active |
| US9421202B2 | Procaspase combination therapy for glioblastoma | Human Necessities | 8 | Active |
| US9592229B2 | Potent anticancer activity via dual compound activation | Human Necessities | 8 | Active |
| US9399035B2 | Procaspase 3 activation by combination therapy | Human Necessities | 6 | Active |
| US10507219B2 | Methods and compositions for dosing in adoptive cell therapy | Chemistry; Metallurgy | 3 | Active |
| US11944647B2 | Articles of manufacture and methods for treatment using adoptive cell therapy | Human Necessities | 2 | Active |
| US11815514B2 | Methods and compositions related to toxicity associated with cell therapy | Chemistry; Metallurgy | 2 | Active |
| US11266739B2 | Methods and compositions for adoptive cell therapy | Chemistry; Metallurgy | 1 | Active |
| US10888560B2 | Procaspase 3 activation by combination therapy | Human Necessities | 0 | Active |
| US11633426B2 | Methods and compositions for dosing in adoptive cell therapy | Chemistry; Metallurgy | 0 | Active |
| US11844798B2 | Procaspase combination therapy for glioblastoma | Human Necessities | 0 | Active |
| US11844769B2 | Use of cysteamine and derivatives thereof to suppress tumor metastases | Human Necessities | 0 | Active |
| US11833147B2 | Procaspase 3 activation by combination therapy | Human Necessities | 0 | Active |
| US10085977B2 | Procaspase 3 activation by combination therapy | Human Necessities | 0 | Active |
| US10874666B2 | Procaspase combination therapy for glioblastoma | Human Necessities | 0 | Active |
| US12163952B2 | Determining toxicity risk in CAR T-cell therapy | Physics | 0 | Active |
| US10085978B2 | Procaspase combination therapy for glioblastoma | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.